Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects

Table 1 Brazilian cohort – clinical characteristics of participants by CAD status

	With CAD	Without CAD	p
Subjects (n)	406	188
Sex: Male (%)	63	50	0.0005
Age (y)	60 ± 11	57 ± 11	0.0001
Diabetes mellitus (%)	48	52	0.35
Fasting plasma glucose (mmol/l)	7 ± 2.78	6.39 ± 1.89	0.03
HbA1c (%)	6.8 ± 1.6	6.6 ± 1.5	0.11
BMI (kg/m²)	27.1 ± 4.6	28.0 ± 5.0	0.06
Dyslipidemia (%)	95	86	0.01
Triglycerides (mmol/l)*	1.47[1.00-1.95]	1.36[0.89-1.84]	0.0002
LDL Cholesterol (mmol/l)	2.59 ± 0.93	2.67 ± 0.88	0.40
HDL Cholesterol (mmol/l)	0.98 ± 0.28	1.09 ± 0.28	0.0001
eGFR(ml/min)	84 ± 24	89 ± 28	0.05
Hypertension (%)	91	90	0.51
Systolic BP (mmHg)	140 ± 24	136 ± 20	0.09
Diastolic BP (mmHg)	80 ± 14	79 ± 13	0.54
Tobacco smoking (%)	57	42	0.003

Data expressed in mean ± SD, except *expressed in median [interquartile range]. CAD coronary artery disease, HbA1c glycated hemoglobin, eGFR estimated glomerular filtration rate. Differences between groups were assessed by Pearson’s chi squared test and ANOVA.

ISSN: 1475-2840